CTSO - CIK 0001175151
Cytosorbents Corp trades as CTSO. In its fiscal 2025 annual report the company posted revenue of $37.06M, up 4.1% from the prior year and net income of -$8.20M. This page tracks Cytosorbents Corp through 959 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Cytosorbents Corp's revenue grew from $9.53M to $37.06M, a compound annual growth rate of 16.3%. Net profit margin expanded from -123.5% to -22.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| Annual report (amended) | 10-K/A | 2026-04-15 |
| Major company event | 8-K | 2026-04-02 |
| Annual report | 10-K | 2026-03-30 |
| Major company event | 8-K | 2026-03-25 |
| SCHEDULE 13G/A | - | 2026-02-13 |
| Insider trade | 4 | 2025-11-20 |
The largest companies sharing Cytosorbents Corp's SEC industry classification (surgical & medical instruments & apparatus).
Cytosorbents Corp reported revenue of $37.06M for fiscal year 2025, an increase of 4.1% year over year.
In its latest fiscal year Cytosorbents Corp reported a net loss of $8.20M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.